Frontiers in surgery · 2026
Meta-analysis of efficacy of probiotics in reducing postoperative infections and improving outcomes in gastrointestinal surgery.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shamim Muhammad
Аннотация
BACKGROUND: Postoperative infections remain a major cause of morbidity and mortality following gastrointestinal surgery. This meta-analysis aims to evaluate the efficacy of perioperative probiotic use in reducing postoperative infections (POI).
METHODS: Eight randomized controlled trials (RCTs) with 755 participants were included. The effect size was calculated as the Odds Ratio (OR) and Risk Ratio (RR) using a random-effects model.
RESULTS: The pooled analysis suggested a potential benefit in reducing overall postoperative infections [OR: 0.57 (95% CI: 0.32-1.01); P = 0.057] and wound infection [OR: 0.61 (95% CI: 0.35-1.06); P = 0.073]. While the overall effect narrowly missed statistical significance, subgroup analysis revealed a statistically significant reduction in POI when multi-strain Lactobacillus and Bifidobacterium formulations were used [RR: 0.64 (95% CI: 0.49-0.83)]. The absolute risk reduction (ARR) for this multi-strain subgroup was 13.5%, corresponding to a highly favorable number needed to treat (NNT) of 7.
CONCLUSION: The current evidence regarding the overall efficacy of perioperative probiotics in decreasing postoperative infectious complications narrowly misses statistical significance. However, the targeted use of multi-strain Lactobacillus and Bifidobacterium formulations significantly reduces the risk of infectious complications. These specific regimens offer a clinically meaningful benefit and support its inclusion in Enhanced Recovery After Surgery (ERAS) protocols for patients undergoing major gastrointestinal surgery.
METHODS: Eight randomized controlled trials (RCTs) with 755 participants were included. The effect size was calculated as the Odds Ratio (OR) and Risk Ratio (RR) using a random-effects model.
RESULTS: The pooled analysis suggested a potential benefit in reducing overall postoperative infections [OR: 0.57 (95% CI: 0.32-1.01); P = 0.057] and wound infection [OR: 0.61 (95% CI: 0.35-1.06); P = 0.073]. While the overall effect narrowly missed statistical significance, subgroup analysis revealed a statistically significant reduction in POI when multi-strain Lactobacillus and Bifidobacterium formulations were used [RR: 0.64 (95% CI: 0.49-0.83)]. The absolute risk reduction (ARR) for this multi-strain subgroup was 13.5%, corresponding to a highly favorable number needed to treat (NNT) of 7.
CONCLUSION: The current evidence regarding the overall efficacy of perioperative probiotics in decreasing postoperative infectious complications narrowly misses statistical significance. However, the targeted use of multi-strain Lactobacillus and Bifidobacterium formulations significantly reduces the risk of infectious complications. These specific regimens offer a clinically meaningful benefit and support its inclusion in Enhanced Recovery After Surgery (ERAS) protocols for patients undergoing major gastrointestinal surgery.